The combination of regorafenib and anti-PD1 therapy demonstrated synergistic antitumor efficacy in the liver cancer models in terms of tumor growth (figure 6A) and animal survival (figure 6B) as compared with either monotherapy. Here, PDCD1 is linked to liver cancer.